Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
McKesson
Farmers Insurance
Federal Trade Commission
Baxter
Harvard Business School
McKinsey
Cantor Fitzgerald
AstraZeneca

Generated: April 26, 2018

DrugPatentWatch Database Preview

Details for Patent: 4,391,802

« Back to Dashboard

Summary for Patent: 4,391,802
Title: Method of treating leukemia or leukemoid diseases
Abstract:A method of leukemia or leukemoid disease treatment by administration of a vitamin D derivative with a hydroxyl group at 1.alpha.-position is disclosed. It is believed that the vitamin D derivative with a hydroxyl group at 1.alpha.-position is capable of treating cancer through redifferentiation of cancer cells and that this capability is inherent in vitamin D derivatives with a hydroxyl group at 1.alpha.-position.
Inventor(s): Suda; Tatsuo (Tachikawa, JP), Hirasawa; Yoshihei (Niigata, JP), Takahashi; Sachio (Niigata, JP), Abe; Etsuko (Tokyo, JP), Konno; Kunio (Tokyo, JP), Aoki; Tadao (Niigata, JP)
Assignee: Chugai Seiyaku Kabushiki Kaisha (Tokyo, JP)
Application Number:06/356,385
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Drugs Protected by US Patent 4,391,802

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 4,391,802

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan56-35218Mar 13, 1981

International Family Members for US Patent 4,391,802

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Japan S57149224 ➤ Sign Up
Japan H0115484 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Harvard Business School
Queensland Health
Chubb
Healthtrust
Express Scripts
Teva
US Department of Justice
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.